Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF

Justin L. Grodin, Anuradha Lala, Susanna R. Stevens, Adam D. DeVore, Lauren B. Cooper, Omar F. AbouEzzeddine, Robert J. Mentz, John D. Groarke, Emer Joyce, Julie L. Rosenthal, Justin M. Vader, W. H.Wilson Tang

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background Hypoalbuminemia is common in patients with chronic heart failure and, as a marker of disease severity, is associated with an adverse prognosis. Whether hypoalbuminemia contributes to (or is associated with) worse outcomes in acute heart failure (AHF) is unclear. We sought to determine the implications of low serum albumin in patients receiving decongestive therapies for AHF. Methods and Results Baseline serum albumin levels were measured in 456 AHF subjects randomized in the DOSE-AHF and ROSE-AHF trials. We assessed the relationship between admission albumin levels (both as a continuous variable and stratified by median albumin [≥3.5 g/dL]) and worsening renal function (WRF), worsening heart failure (WHF), and clinical decongestion by 72 hours; 7-day cardiorenal biomarkers; and post-discharge outcomes. The mean baseline albumin level was 3.5 ± 0.5 g/dL. Albumin was not associated with WRF, WHF, or clinical decongestion by 72 hours. Furthermore, there was no association between continuous albumin levels and symptom change according to visual analog scale or weight change by 72 hours. Albumin was not associated with 60-day mortality, rehospitalization, or unscheduled emergency room visits. Conclusions Baseline serum albumin levels were not associated with short-term clinical outcomes for AHF patients undergoing decongestive therapies. These data suggest that serum albumin may not be a helpful tool to guide decongestion strategies.

Original languageEnglish (US)
Pages (from-to)884-890
Number of pages7
JournalJournal of Cardiac Failure
Volume22
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Serum Albumin
Heart Failure
Albumins
Hypoalbuminemia
Kidney
Visual Analog Scale
Hospital Emergency Service
Biomarkers
Weights and Measures
Mortality
Therapeutics

Keywords

  • diuretics
  • Heart failure
  • proteins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Grodin, J. L., Lala, A., Stevens, S. R., DeVore, A. D., Cooper, L. B., AbouEzzeddine, O. F., ... Tang, W. H. W. (2016). Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF. Journal of Cardiac Failure, 22(11), 884-890. https://doi.org/10.1016/j.cardfail.2016.01.015

Clinical Implications of Serum Albumin Levels in Acute Heart Failure : Insights From DOSE-AHF and ROSE-AHF. / Grodin, Justin L.; Lala, Anuradha; Stevens, Susanna R.; DeVore, Adam D.; Cooper, Lauren B.; AbouEzzeddine, Omar F.; Mentz, Robert J.; Groarke, John D.; Joyce, Emer; Rosenthal, Julie L.; Vader, Justin M.; Tang, W. H.Wilson.

In: Journal of Cardiac Failure, Vol. 22, No. 11, 01.11.2016, p. 884-890.

Research output: Contribution to journalArticle

Grodin, JL, Lala, A, Stevens, SR, DeVore, AD, Cooper, LB, AbouEzzeddine, OF, Mentz, RJ, Groarke, JD, Joyce, E, Rosenthal, JL, Vader, JM & Tang, WHW 2016, 'Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF', Journal of Cardiac Failure, vol. 22, no. 11, pp. 884-890. https://doi.org/10.1016/j.cardfail.2016.01.015
Grodin, Justin L. ; Lala, Anuradha ; Stevens, Susanna R. ; DeVore, Adam D. ; Cooper, Lauren B. ; AbouEzzeddine, Omar F. ; Mentz, Robert J. ; Groarke, John D. ; Joyce, Emer ; Rosenthal, Julie L. ; Vader, Justin M. ; Tang, W. H.Wilson. / Clinical Implications of Serum Albumin Levels in Acute Heart Failure : Insights From DOSE-AHF and ROSE-AHF. In: Journal of Cardiac Failure. 2016 ; Vol. 22, No. 11. pp. 884-890.
@article{6eb34b8d246e4c45bcd8fe2623be784d,
title = "Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF",
abstract = "Background Hypoalbuminemia is common in patients with chronic heart failure and, as a marker of disease severity, is associated with an adverse prognosis. Whether hypoalbuminemia contributes to (or is associated with) worse outcomes in acute heart failure (AHF) is unclear. We sought to determine the implications of low serum albumin in patients receiving decongestive therapies for AHF. Methods and Results Baseline serum albumin levels were measured in 456 AHF subjects randomized in the DOSE-AHF and ROSE-AHF trials. We assessed the relationship between admission albumin levels (both as a continuous variable and stratified by median albumin [≥3.5 g/dL]) and worsening renal function (WRF), worsening heart failure (WHF), and clinical decongestion by 72 hours; 7-day cardiorenal biomarkers; and post-discharge outcomes. The mean baseline albumin level was 3.5 ± 0.5 g/dL. Albumin was not associated with WRF, WHF, or clinical decongestion by 72 hours. Furthermore, there was no association between continuous albumin levels and symptom change according to visual analog scale or weight change by 72 hours. Albumin was not associated with 60-day mortality, rehospitalization, or unscheduled emergency room visits. Conclusions Baseline serum albumin levels were not associated with short-term clinical outcomes for AHF patients undergoing decongestive therapies. These data suggest that serum albumin may not be a helpful tool to guide decongestion strategies.",
keywords = "diuretics, Heart failure, proteins",
author = "Grodin, {Justin L.} and Anuradha Lala and Stevens, {Susanna R.} and DeVore, {Adam D.} and Cooper, {Lauren B.} and AbouEzzeddine, {Omar F.} and Mentz, {Robert J.} and Groarke, {John D.} and Emer Joyce and Rosenthal, {Julie L.} and Vader, {Justin M.} and Tang, {W. H.Wilson}",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.cardfail.2016.01.015",
language = "English (US)",
volume = "22",
pages = "884--890",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "11",

}

TY - JOUR

T1 - Clinical Implications of Serum Albumin Levels in Acute Heart Failure

T2 - Insights From DOSE-AHF and ROSE-AHF

AU - Grodin, Justin L.

AU - Lala, Anuradha

AU - Stevens, Susanna R.

AU - DeVore, Adam D.

AU - Cooper, Lauren B.

AU - AbouEzzeddine, Omar F.

AU - Mentz, Robert J.

AU - Groarke, John D.

AU - Joyce, Emer

AU - Rosenthal, Julie L.

AU - Vader, Justin M.

AU - Tang, W. H.Wilson

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background Hypoalbuminemia is common in patients with chronic heart failure and, as a marker of disease severity, is associated with an adverse prognosis. Whether hypoalbuminemia contributes to (or is associated with) worse outcomes in acute heart failure (AHF) is unclear. We sought to determine the implications of low serum albumin in patients receiving decongestive therapies for AHF. Methods and Results Baseline serum albumin levels were measured in 456 AHF subjects randomized in the DOSE-AHF and ROSE-AHF trials. We assessed the relationship between admission albumin levels (both as a continuous variable and stratified by median albumin [≥3.5 g/dL]) and worsening renal function (WRF), worsening heart failure (WHF), and clinical decongestion by 72 hours; 7-day cardiorenal biomarkers; and post-discharge outcomes. The mean baseline albumin level was 3.5 ± 0.5 g/dL. Albumin was not associated with WRF, WHF, or clinical decongestion by 72 hours. Furthermore, there was no association between continuous albumin levels and symptom change according to visual analog scale or weight change by 72 hours. Albumin was not associated with 60-day mortality, rehospitalization, or unscheduled emergency room visits. Conclusions Baseline serum albumin levels were not associated with short-term clinical outcomes for AHF patients undergoing decongestive therapies. These data suggest that serum albumin may not be a helpful tool to guide decongestion strategies.

AB - Background Hypoalbuminemia is common in patients with chronic heart failure and, as a marker of disease severity, is associated with an adverse prognosis. Whether hypoalbuminemia contributes to (or is associated with) worse outcomes in acute heart failure (AHF) is unclear. We sought to determine the implications of low serum albumin in patients receiving decongestive therapies for AHF. Methods and Results Baseline serum albumin levels were measured in 456 AHF subjects randomized in the DOSE-AHF and ROSE-AHF trials. We assessed the relationship between admission albumin levels (both as a continuous variable and stratified by median albumin [≥3.5 g/dL]) and worsening renal function (WRF), worsening heart failure (WHF), and clinical decongestion by 72 hours; 7-day cardiorenal biomarkers; and post-discharge outcomes. The mean baseline albumin level was 3.5 ± 0.5 g/dL. Albumin was not associated with WRF, WHF, or clinical decongestion by 72 hours. Furthermore, there was no association between continuous albumin levels and symptom change according to visual analog scale or weight change by 72 hours. Albumin was not associated with 60-day mortality, rehospitalization, or unscheduled emergency room visits. Conclusions Baseline serum albumin levels were not associated with short-term clinical outcomes for AHF patients undergoing decongestive therapies. These data suggest that serum albumin may not be a helpful tool to guide decongestion strategies.

KW - diuretics

KW - Heart failure

KW - proteins

UR - http://www.scopus.com/inward/record.url?scp=84959276564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959276564&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2016.01.015

DO - 10.1016/j.cardfail.2016.01.015

M3 - Article

C2 - 26844764

AN - SCOPUS:84959276564

VL - 22

SP - 884

EP - 890

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 11

ER -